Who doesn’t want to live forever? The idea is appealing to many and it now seems that researchers from Washington University in St. Louis and Keio University in Japan have come across an anti-aging drug that just might add years to our lives.
Nicotinamide mono nucleotide (NMN) is a chemical compound that has been observed to slow down the aging process in mice and extend their lives, but the real question is: can it do the same for humans?
A joint clinical study will set out to answer this and to test the effectiveness and safety of NMN in humans.
Ten healthy test subjects will begin trials in July where they will be given NMN to see if there is any improvement in bodily functions.
If it works it means that, in time, this will be the very first valid anti-aging drug intervention treatment available on the market. Not only will this impact the lives of humans in general, but there are also economic benefits to be had. In an aging society, there are a lot of healthcare costs to consider, to the tune of billions of dollars in developed countries. If these trials are successful and aging can be slowed down or reversed, that’s a lot of money potentially saved in medical and nursing needs.
If NMN is found to be safe for humans, it would be delivered to the market as a food source, though this won’t happen for quite some time yet. Nevertheless, the idea itself is intriguing and if it ends up being an elixir of life or a fountain of youth for humans as it is for mice, then it could potentially change the landscape of health and medical care as we currently know it.
But let’s not get too far ahead of ourselves. The anti-aging drug trial first needs to undergo a review by the Research Ethics Committee at Keio University. The Committee will assess the researchers’ plans and decide whether they are appropriate and can be given the go-ahead.
Source for Today’s Article:
“1st Clinical Trial Set for ‘Anti-Aging Compound,’” The Japan News web site; http://www.the-japan-news.com/news/article/0003030620, last accessed June 23, 2016.